雷帕鸣的效果如何

It is a new, powerful, low-toxic macrolide immunosuppressive drug produced by Pfizer. It has been on the market in my country for many years. It is mainly used clinically to prevent rejection of kidney transplants. It is one of the best choices when liver or kidney insufficiency occurs after organ transplantation or when CNI cannot reach the ideal drug concentration.

In addition to Pfizer's original drug Rapamide, more and more patients are choosing to buy the relatively low-priced generic drug Rapamide produced by Biocon India. However, there are also some patients who do not understand what generic drugs are and how effective Rapamide India's Biocon is.

Biocon India is one of the top three biotech companies in India. Its fully integrated business model spans the entire pharmaceutical value chain, from preclinical discovery to clinical development and commercialization. The business is customized research, clinical development and biopharmaceuticals to provide multiple revenue streams to balance development, drive innovation, deliver products and accelerate growth. Bringing differentiated, high-quality and affordable medical products to communities around the world. The effect of Biocanrepamin is basically the same as that of the original drug, so patients do not need to worry.

Rapamin combined with low-dose cyclosporine A is a better immunosuppressive treatment option after kidney transplantation, and the use of rapamin can reduce the dose of CNI. After renal transplantation, it is safe and effective to control the steady-state trough concentration of rapamycin at 4-8ng/ml or 5-8ng/ml. Rapamin also reduces the incidence of non-melanoma skin cancer after kidney transplantation. In addition, rapamycin has also achieved good anti-rejection effects after heart transplantation, lung transplantation, corneal transplantation and other transplants, but the therapeutic concentration has not been reported.

It can be seen that its use in kidney transplant patients can not only effectively reduce the risk of rejection, but is also relatively safe, making it a good choice for patients after organ transplantation.

Recommended related hot articles: /newsDetail/86876.html